Somatostatin Receptor Type 4 (SSTR4) - Pipeline Review, H1 2017

Market: Pharmaceuticals and Healthcare

Global, 39 pages report, published by Global Markets Direct

Keywords : Somatostatin Receptor Type 4 (SSTR4) Therapeutic Products under Development, Key Players in Somatostatin Receptor Type 4 (SSTR4) Therapeutics, Somatostatin Receptor Type 4 (SSTR4) Pipeline Overview, Somatostatin Receptor Type 4 (SSTR4) Pipeline, Somatostatin Receptor Type 4 (SSTR4) Pipeline Assessment

Report ThumbnailJune-2017
Somatostatin Receptor Type 4 (SSTR4) - Pipeline Review, H1 2017

Summary

According to the recently published report 'Somatostatin Receptor Type 4 (SSTR4) - Pipeline Review, H1 2017'; Somatostatin Receptor Type 4 (SSTR4) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes.

Somatostatin Receptor Type 4 (SSTR4) - Somatostatin receptor type 4 is a protein encoded by the SSTR4 gene. The activity of receptor is mediated by G proteins which inhibits adenylyl cyclase. It mediates antiproliferative action of somatostatin in tumor cells. It is functionally coupled to inhibition of adenylate cyclase and activation of both arachidonate release and mitogen-activated protein (MAP) kinase cascade.

The report 'Somatostatin Receptor Type 4 (SSTR4) - Pipeline Review, H1 2017' outlays comprehensive information on the Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 1 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Hormonal Disorders, Metabolic Disorders and Oncology which include indications Chronic Pain, Acromegaly, Neuropathic Pain, Alzheimer's Disease, Cognitive Disorders, Dementia, Diabetic Retinopathy, Gastrointestinal Tumor, Neuroendocrine Tumors, Pancreatic Tumor and Pituitary ACTH Hypersecretion (Cushing Disease).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Somatostatin Receptor Type 4 (SSTR4)
- The report reviews Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Somatostatin Receptor Type 4 (SSTR4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Somatostatin Receptor Type 4 (SSTR4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • List of Figures
  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Top 10 Indications, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
  • List of Tables
  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Indication, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products under Investigation by Universities/Institutes, H1 2017
  • Products under Investigation by Universities/Institutes, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pipeline by Crinetics Pharmaceuticals Inc, H1 2017
  • Pipeline by Strongbridge Biopharma plc, H1 2017
  • Dormant Products, H1 2017
  • Dormant Products, H1 2017 (Contd..1), H1 2017
  • Dormant Products, H1 2017 (Contd..2), H1 2017
  • Table of Contents
  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • Somatostatin Receptor Type 4 (SSTR4) - Overview
  • Somatostatin Receptor Type 4 (SSTR4) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Somatostatin Receptor Type 4 (SSTR4) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Somatostatin Receptor Type 4 (SSTR4) - Companies Involved in Therapeutics Development
  • Crinetics Pharmaceuticals Inc
  • Strongbridge Biopharma plc
  • Somatostatin Receptor Type 4 (SSTR4) - Drug Profiles
  • CNTX-0290 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NNC-269100 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize SSTR2 and SSTR4 for Chronic Pain and Neuropathic Pain - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize SSTR4 for Neuropathic Pain and Chronic Pain - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • veldoreotide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Somatostatin Receptor Type 4 (SSTR4) - Dormant Products
  • Somatostatin Receptor Type 4 (SSTR4) - Product Development Milestones
  • Featured News & Press Releases
  • May 31, 2016: Strongbridge Biopharma plc Announces Presentation of COR-005 Data at the European Congress of Endocrinology
  • Apr 27, 2015: Crinetics Pharmaceuticals Awarded NIH Fast-Track Grant to Develop Somatostatin Receptor Agonist Drugs for Chronic Pain
  • Apr 22, 2014: Aspireo Reports Data in Further Phase Ib Study
  • Sep 25, 2013: FDA Grants Orphan Drug Designation for Aspireo’s Somatoprim
  • Jun 18, 2013: Aspireo Reports Start of Further Phase I Study in Healthy Volunteers
  • Apr 03, 2013: Aspireo Pharma Reports Somatoprim Phase IIa Proof Of Concept Results In Acromegaly
  • Jan 07, 2013: Aspireo Pharma Reports Phase Ib Interim Data For Somatoprim
  • Nov 26, 2012: Aspireo Pharma Announces EMA's Committee For Orphan Medicinal Products Recommends Orphan Medicinal Product Designation For Somatoprim
  • Nov 06, 2012: Aspireo Pharma Starts Somatoprim Phase IIa Study In Acromegaly Patients
  • Sep 28, 2012: Evotec And Aspireo Pharma Enter Into Strategic Advisory Agreement For Somatoprim
  • Jun 26, 2012: Somatoprim is a potent agonist of Somatostatin Receptors 2 and 5
  • Apr 05, 2012: Aspireo Starts Phase I Multi Ascending Dose Study with Somatoprim
  • Feb 26, 2009: DeveloGen Reports Positive Phase I Clinical Trial Results for DG3173
  • Oct 08, 2008: DeveloGen Announces Completion Of A Phase I Clinical Trial Of DG3173, A Novel Somatostatin Analogue For The Treatment Of Acromegaly
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

Please select a license type

Share

Related Products

Global Markets DirectSomatostatin Receptor Type 4 (SSTR4) - Pipeline Review, H1 2017Product ThumbnailSomatostatin Receptor Type 4 (SSTR4) - Pipeline Review, H1 2017, Industry ReportProduct #: 829018
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved